# A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

> **NCT00447980** · PHASE2 · COMPLETED · sponsor: **Neurotech Pharmaceuticals** · enrollment: 73 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** NT-501
- **DRUG:** NT-501

## Key facts

- **NCT ID:** NCT00447980
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-22
- **Primary completion:** 2010-04-19
- **Final completion:** 2010-04-19
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447980, "A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00447980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*